Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Jun;69(6):1136–1140. doi: 10.1038/bjc.1994.223

Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.

J L Pujol 1, A Monnier 1, J Berille 1, M L Cerrina 1, J Y Douillard 1, A Rivière 1, A Grandgirard 1, S Gouva 1, J P Bizzari 1, T Le Chevalier 1
PMCID: PMC1969429  PMID: 8198982

Abstract

A phase II study was designed to evaluate objective response rate and toxicity of fotemustine as single-drug chemotherapy in non-small-cell lung cancer. Eighty-seven patients with unresectable non-small-cell lung cancer took part in the study. Seventy-seven were evaluable for response. Of these, 60% had received prior chemotherapy and 74% had metastatic disease. Moreover, 22 patients had central nervous system metastases (of whom 12 were evaluable for this site). Treatment consisted of fotemustine 100 mg m-2 administered on days 1 and 8 followed by a 5 week rest period. Afterwards, responding or stabilised patients received fotemustine 100 mg m-2 every 3 weeks as a maintenance therapy. Toxicity and quality of life were recorded during therapy. Thirteen patients (17%; 95% CI 9-25%) had an objective response (11% for pretreated, 26% for non-pretreated) with a median duration of 22 weeks (range 7-41 weeks). Two objective responses were observed among the 12 patients with evaluable brain metastases. No response was observed among the 14 patients with adenocarcinoma. Haematological, gastrointestinal, hepatic and renal toxicities were mild to moderate and manageable. The most frequent biological adverse reactions were delayed thrombocytopenia and neutropenia. Quality of life did not significantly decrease during the first 6 treatment weeks. Moreover, it remained stable during the study period in patients with response or stabilisation, whereas it significantly decreased in patients who experienced progression of the disease. Fotemustine is feasible for single-drug chemotherapy in non-small-cell lung cancer even though poor prognostic variables such as brain metastases are present. It can be administered on an outpatient basis and toxicity is moderate and manageable. Thus, fotemustine can be considered as a putative drug in further combinations.

Full text

PDF
1136

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avril M. F., Bonneterre J., Delaunay M., Grosshans E., Fumoleua P., Israel L., Bugat R., Namer M., Cupissol D., Kerbrat P. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group. Cancer Chemother Pharmacol. 1990;27(2):81–84. doi: 10.1007/BF00689087. [DOI] [PubMed] [Google Scholar]
  2. Donnadieu N., Paesmans M., Sculier J. P. Chimiothérapie des cancers bronchiques non à petites cellules. Meta-analyse de la littérature en fonction de l'extension de la maladie. Rev Mal Respir. 1991;8(2):197–204. [PubMed] [Google Scholar]
  3. Frenay M., Giroux B., Khoury S., Derlon J. M., Namer M. Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer. 1991;27(7):852–856. doi: 10.1016/0277-5379(91)90133-x. [DOI] [PubMed] [Google Scholar]
  4. GEHAN E. A. The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis. 1961 Apr;13:346–353. doi: 10.1016/0021-9681(61)90060-1. [DOI] [PubMed] [Google Scholar]
  5. Hansen H. H., Rørth M. Lung cancer. Cancer Chemother Biol Response Modif. 1988;10:222–240. [PubMed] [Google Scholar]
  6. Ihde D. C. Chemotherapy of lung cancer. N Engl J Med. 1992 Nov 12;327(20):1434–1441. doi: 10.1056/NEJM199211123272006. [DOI] [PubMed] [Google Scholar]
  7. Jacquillat C., Khayat D., Banzet P., Weil M., Avril M. F., Fumoleau P., Namer M., Bonneterre J., Kerbrat P., Bonerandi J. J. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol. 1990;25(4):263–266. doi: 10.1007/BF00684883. [DOI] [PubMed] [Google Scholar]
  8. Jacquillat C., Khayat D., Banzet P., Weil M., Fumoleau P., Avril M. F., Namer M., Bonneterre J., Kerbrat P., Bonerandi J. J. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990 Nov 1;66(9):1873–1878. doi: 10.1002/1097-0142(19901101)66:9<1873::aid-cncr2820660904>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  9. Le Chevalier T., Zabbe C., Gouva S., Cerrina M. L., Quoix E., Riviere A., Berthaud P., Prache C., Berille J. Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma. Eur J Cancer Clin Oncol. 1989 Nov;25(11):1651–1652. doi: 10.1016/0277-5379(89)90312-x. [DOI] [PubMed] [Google Scholar]
  10. Pujol J. L., Rossi J. F., Le Chevalier T., Daurès J. P., Rouanet P., Douillard J. Y., Dubois J. B., Arriagada R., Mary H., Godard P. Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer. Eur J Cancer. 1990;26(7):798–801. doi: 10.1016/0277-5379(90)90155-m. [DOI] [PubMed] [Google Scholar]
  11. Rapp E., Pater J. L., Willan A., Cormier Y., Murray N., Evans W. K., Hodson D. I., Clark D. A., Feld R., Arnold A. M. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol. 1988 Apr;6(4):633–641. doi: 10.1200/JCO.1988.6.4.633. [DOI] [PubMed] [Google Scholar]
  12. Schipper H., Clinch J., McMurray A., Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol. 1984 May;2(5):472–483. doi: 10.1200/JCO.1984.2.5.472. [DOI] [PubMed] [Google Scholar]
  13. Souquet P. J., Chauvin F., Boissel J. P., Cellerino R., Cormier Y., Ganz P. A., Kaasa S., Pater J. L., Quoix E., Rapp E. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 1993 Jul 3;342(8862):19–21. doi: 10.1016/0140-6736(93)91882-m. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES